was computed again for each cell line after averaging remaining replicates, and the cell lines 8 For quality control and normalization, exogenously defined nonessential genes 22 were 181 used as negative controls, and common essential genes 23, 24 were used as positive controls. The 182 gene level dependency scores were inferred by running the computational tool CERES 20 .
183
CERES was developed to computationally correct the copy-number effect and to infer true 
189
The CERES gene dependency data was further scaled to the -1 value of the median of 190 common essential genes in each cell line, and then transformed into z-scores so that each gene 191 had mean = 0 and variance = 1. Next the first five principal components of the resulting data 192 were removed, the prior means of genes were restored, and the data were scaled again so the 193 median of common essentials in each cell lines was -1. The pan-dependent genes were 194 identified as those genes for whom 90% of cell lines rank the gene above a dependency cutoff 195 determined from the central minimum in a histogram of gene ranks in their 90th percentile least 196 dependent line. For each CERES gene score, the probability that the score represents a true 197 dependency or not was inferred based on the expectation-maximization algorithm.
198
The differential dependency gene level scores for the T-ALL lineage were determined for 
250

Single-sample Gene Set Enrichment Analysis for T-ALL Dependencies
251
A single-sample GSEA (ssGSEA) analysis 37, 38 
279
Samples were vortexed at 4 degrees, followed by centrifugation at 4C for 10 minutes.
12
Dried cell extracts were resuspended in 50 μL HPLC grade water. 
352
One-carbon folate metabolism is a dependency in T-ALL.
353
To identify selective pathway dependencies for T-ALL we used CRISPR-Cas9 whole pathways for T-ALL compared to other cancers. Inhibition of these pathways would be predicted to be more therapeutically effective in T-ALL compared to other tumors. The one-carbon folate,
16
SHMT inhibition on gene expression. We treated the KOPTK1 cell line with RZ-2994 for 1 and 3 385 days and performed RNA sequencing analysis. RZ-2994 treatment resulted in changes in 386 pathways associated with amino acid metabolism ( Fig. 2D and Supplementary Fig. 4A ), MYC 387 targets ( Fig. 2E and Supplementary Fig. 4B ) and associated with cell cycle arrest ( Fig. 2F and 388 Supplementary Fig. 4C ). These changes were more pronounced after 3 days of treatment.
389
Inhibition of SHMT1 and SHMT2 impairs glycine and formate synthesis, which in turn 390 can impede nucleotide production 19, 44 . We performed metabolite profiling of PF382, KOPTK1 391 and RPMI8402 cell lines treated with RZ-2994 for 3 days and observed changes in
392
intermediates that involve the one-carbon folate pathway ( Supplementary Fig. 5 ). We focused 393 on metabolic changes that were common among the three cell lines as those are more likely to 394 contribute to the RZ-2994-related effect on cell growth. Consistent with SHMT1 and SHMT2 395 inhibition, we found glycine levels were decreased with an increase in serine levels. We also 396 observed increases in the purine precursors AICAR and GAR ( 
405
Loss of both SHMT1 and SHMT2 is necessary to impair proliferation of T-ALL.
406
Enzymes of the mitochondrial one-carbon folate pathway are highly expressed in 407 cancer, 45, 46 and their expression has been associated with poor survival 46 . We have previously 408 shown MTHFD2 and enzymes of the one-carbon folate pathway to be highly expressed in AML,
409
with inhibition of MTHFD2 leading to a decrease in AML viability in vitro and in vivo 13 .
410
Redundancy of SHMT1 and SHMT2 enzymes has been shown in HEK293T cells and HCT-116 18 dosing 18 . We thus performed pharmacokinetic analysis of RZ-2994 to assess its bioavailability 437 for use as a tool compound in vivo. After injection of RZ-2994 20 mg/kg IP (intraperitoneally), 438 serial levels were measured, with a t 1/2 =5.9 hours and drug levels shown in Figure 5D . We next 439 performed a dose escalation study, where NSG mice were treated with up to 100 mg/kg without 440 toxicity for 1 week. We next conducted a pilot experiment to test whether RZ-2994 treatment 441 results in predicted metabolic changes in an orthotopic RPMI8402 mouse model, with RZ-2994 442 dosed at 100 mg/kg IP daily. Three mice per group were treated for 1 week and selected 443 metabolites profiled. In line with the in vitro data, RZ-2994 led to a trend toward increased GAR 444 and dUMP, and an increase in the dUMP/dTMP ratio, consistent with disrupting one-carbon 445 folate metabolism in vivo (Fig. 5E ).
446
We next investigated the in vivo efficacy of RZ-2994 in a T-ALL animal model.
447
Luciferase expressing RPMI8402 cells were injected via tail vein into irradiated NSG mice.
448
Leukemia establishment was determined using bioluminescent imaging, and mice were 449 randomized into two groups, vehicle versus RZ-2994 treatment once disease was established.
450
Mice were treated with 100 mg/kg IP daily for 2 weeks and disease burden evaluated. The drug 451 was well tolerated, with stable weights for both the vehicle and treatment cohorts ( Fig. 5F ). RZ-452 2994 treatment led to a decrease in leukemia burden in the bone marrow and spleen ( Fig. 5G ),
453
supporting further compound optimization and pre-clinical evaluation of this pathway in T-ALL.
455
SHMT inhibition is efficacious in the setting of methotrexate resistance.
456
Methotrexate is a backbone of ALL chemotherapy treatment. 
482
In this study, we identified the one-carbon folate pathway as an enriched pathway 483 dependency in T-ALL. One-carbon folate metabolism is critical for nucleotide synthesis, support 
503
The mechanistic role of SHMT1 and SHMT2 that is specific to T-ALL pathogenesis 504 remains elusive. MTHFD2 is classically described as contributing to one-carbon unit production 505 through conversion of serine to glycine by SHMT2 and production of formate as a product of Interestingly, there was no depletion of SAM and methionine with RZ-2994 treatment 516 ( Supplementary Fig. 5 ). Maddocks et al. showed that the one-carbon folate pathway does not 517 contribute one-carbon units to methionine in the presence of methionine replete conditions in 518 cells in culture 57 , likely explaining the lack of methionine depletion in RZ-2994 treated cells.
519
Chemotherapy resistance is a key factor in cancer treatment failure. Inhibitors of the 520 one-carbon folate pathway are used for treatment of cancers including ALL, osteosarcoma, 521 breast, lung and many others, though predictors of response are not evaluated pre-treatment.
522
We showed that T-ALL cell lines that are resistant to methotrexate remain sensitive to another 523 inhibitor of the one-carbon folate pathway. It is also possible that resistance to inhibition of the 524 one-carbon folate pathway may be overcome with novel inhibitors of this pathway though further 525 in vivo testing is necessary.
526
RZ-2994, a recently developed inhibitor of SHMT1 and SHMT2, was reported to have 527 poor stability in liver microsome assays 19 . We performed a PK study, however, that showed a likely necessary for improved in vivo efficacy. In addition, RZ-2994 causes cell cycle arrest.
530
Active drug combinations with an SHMT1/2 inhibitor with other drugs that cause cell death may 531 be necessary to maximize efficacy of this approach. Often new drugs are combined with 532 standard chemotherapy for treatment of patients with leukemia. However, the combination of 533 RZ-2994 with standard chemotherapy, which is most toxic to rapidly proliferating cells, may be 534 antagonistic and careful testing of combinations will be necessary for clinical implementation of 535 an optimized inhibitor.
536
In summary, the combination of unbiased genome-wide screening identifying the one- 
762
Cells were grown over the course of 6 days and viability assessed by an ATP-based assay. (3) blood_CML (6) blood_BALL (7) lymphocyte_lymphoma_unspecified (3) breast (32) hematopoietic_notTALL (73) multiple_myeloma (20) blood_AML (20) lymphocyte_non_hodgkin_lymphoma (13) gastric (25) lung_SCLC (15) bone_Ewing (15) bile_duct (15) colorectal (33) soft_tissue_rhabdomyosarcoma (11) glioma_oligodendroglioma (2) kidney (23) thyroid (4) lung_NSCLC (73) cervix (6) esophagus (24) glioma (5) skin (52) solid (613) pancreas (28) lymphocyte_hodgkin_lymphoma (2) soft_tissue_synovial_sarcoma (5) lung_mesothelioma (8) urinary_tract (29) upper_aerodigestive (29) liver (22) PNS_neuroblastoma (18) soft_tissue_malignant_rhabdoid_tumor (3) ovary (39) soft_tissue_ATRT (5) glioma_astrocytoma (10) soft_tissue_liposarcoma (3) CNS_meningioma (2) uterus (19) glioma_glioblastoma (25) bone_osteo (8) eye (2) CNS_medulloblastoma (8) bone_chordoma (4) soft_tissue_leiomyosarcoma (2) Avana 19Q4 
